Skip to main content

RGC · Regencell Bioscience Holdings Ltd · Metrics

Track RGC — free
$7.00 +0.18 (+2.64%)
Market Cap
$3.05B
Shares
494.49M
Volume · Oct 5 307.15K Avg daily vol (3M) 232.5K

RGC metrics

39 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.82
Market cap
$3.05B

Price action

20 metrics
Price change (1W)
+10.5%
Price change (30D)
+0.0%
Price change (3M)
+7.1%
Price change (6M)
-77.9%
Price change (YTD)
-67.5%
Price change (1Y)
-57.8%
Trailing year
Price change (5Y)
—
52-week high
$52.88
52-week low
$4.78
Change from 52-week high
-87.1%
Change from 52-week low
+42.7%
Annualized volatility
145.7%
Annualized volatility (3M)
93.2%
Beta
1.5
RSI (14D)
64.3
Price vs SMA 50
+17.3%
Price vs SMA 200
-64.4%
Avg volume (3M)
232,497
Relative volume
1.9
Average dollar volume
$1.37M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
494.49M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
627.7
reciprocal yield 0.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.01

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.0%
Year over year
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-73.7%
Return on assets
-62.3%
Debt / equity
—
Current ratio
7.4
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
7.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$2.42M
Total assets
$5.76M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
36
13F filer change QoQ
+2
Institutional ownership
0.3%

Short interest

3 metrics
Short interest
0.2%
Latest settlement · 3.1 days to cover
Days to cover
3.1d
Short-squeeze score
43 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1829667 CUSIP G7487R100 Visit website Investor relations